Abstract:Background Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. Methods Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. Findings The discovery cohort comprised 385 patients (mean age 63.6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60.7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0.90 and corresponding negative predictive value of 0.91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85.7 mL (95% CI 6.9 to 164.4) and those with a high-risk signature experienced an FVC change of -227.1 mL (-286.7 to -167.5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. Interpretation 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

Lung function trajectory in progressive fibrosing interstitial lung disease

Proportion and predictors of FVC decline in patients with interstitial lung disease

Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

Progression of fibrosing interstitial lung disease

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease

The natural history of progressive fibrosing interstitial lung diseases

Relevance Analysis of Clinical and Lung Function Parameters Changing and Prognosis of Idiopathic Pulmonary Fibrosis.

Risk factors for progression of pulmonary fibrosis: a single-centered, retrospective study

Factors influencing long-term outcomes in fibrotic interstitial lung disease (F-ILD) diagnosed through multidisciplinary discussion (MDD): a prospective cohort study

Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease

Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study

Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Long-term functional course of Sjögren's disease-associated interstitial lung disease

Evaluating the Progressive Factor's Impact on IPF Patients Treated with Antifibrotic Agents Over One Year